Therapy News and Research

RSS

$Heart failure patients with moderate ejection fractions may benefit from CRT$

Heart failure patients with moderate ejection fractions may benefit from CRT

Early findings from a Medtronic, Inc. sponsored study show heart failure patients with moderate ejection fractions, over 35 percent, may receive comparable benefits from cardiac resynchronization therapy (CRT) as compared to those with low ejection fractions of equal to or less than 35 percent.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

BCLI collaborates with HBI to complete pre-clinical safety experiments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into a strategic agreement with Harlan Biotech Israel Ltd (HBI), a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

15 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

HFSA meeting highlights increased risk of heart failure among childhood cancer survivors

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion titled "Cardiovascular Disease in Survivors of Childhood Cancer" presented by Dr. Ming Hui Chen, Director, Stress Echocardiography Program and Program for Cardiac Health in Cancer Survivors, Children's Hospital Boston.

15 Sep 2009

Implantable defibrillator therapy not beneficial for women with heart failure

Implantable cardioverter-defibrillators do not appear to be associated with a reduced risk of death in women with advanced heart failure, according to a meta-analysis of previously published research in the September 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Sep 2009

Mantra medicine tool helps patients in healing process

Dr. Mitchell Earl Gibson, a board-certified medical doctor in High Point, North Carolina, has formed a company that creates mantra and prayer-meditation-based recordings.

15 Sep 2009

Extension study data on Fampridine-SR drug

Data from two long-term open-label extension studies of Fampridine-SR show that 86.0% of participants remained on therapy after a maximum treatment time of 15 months in study MS-F204EXT, and 69.5% remained on therapy after a maximum treatment time of 36 months in study MS-F203EXT.

15 Sep 2009

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

CPEX Pharmaceuticals, Inc. (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7, 2009.

15 Sep 2009

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from their Huntington’s disease program at the 2009 World Congress on Huntington’s Disease held September 12-15, 2009 in Vancouver, British Columbia.

15 Sep 2009

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

A study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned, according to Ozonics International, LLC, a veteran-owned biotechnology company engaged in the research and development of ozone-based medical therapies.

15 Sep 2009

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

In light of the economy and rising unemployment, people are looking to cut costs wherever they can. As the costs of many surgeries and procedures continue to rise in the US, many are looking for cheaper alternatives abroad. This big business is known as "medical tourism," and often promises healthcare options at a fraction of the cost as in the United States. However, this is one area where bargain shopping is not recommended, counsels Dr. David B. Samadi, Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

15 Sep 2009

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.

15 Sep 2009

IMPROVE HF clinical trial results presented at annual HFSA meeting

Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.

15 Sep 2009

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product.

15 Sep 2009

Forest Laboratories places Armour Thyroid medication on back order

Forest Laboratories, Inc., the maker of the widely used hormone therapy drug, Armour® Thyroid, recently announced it has placed the medication on back order. The company said on its website that it does not have enough of the active ingredient, powdered Thyroid gland, in stock to produce the medication.

15 Sep 2009

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Cardium Therapeutics (NYSE Amex: CXM) today reported on preclinical findings published in the scientific journal, Gene Therapy, demonstrating that Cardium's Gene Activated Matrix(TM) or GAM(TM) technology accelerates periodontal tissue regeneration of oral implant-supporting wounds.

15 Sep 2009

Wake Pharma to present clinical evidence in the treatment of wounds using Wound-Be-Gone at SAWC

Wake Pharma US announced today that clinical evidence in the treatment of wounds using Wound-Be-Gone® will be presented at the fall Society for Advance Wound Care Conference. The SAWC is being held in Washington, DC from September 16-18, 2009. The clinical evidence and data will be presented through posters on display during the meeting.

15 Sep 2009

New generation CPAP mask to aid sleep apnoea patients from ResMed

ResMed, a leading manufacturer of sleep and respiratory medical equipment, today announced that it has introduced a new generation continuous positive airway pressure (CPAP) mask designed to improve the patient experience and compliance. With minimal contact on the face and a sleek design, Swift FX is expected to help sleep apnoea patients overcome issues related to wearing a mask at night and effectively providing them with a good night’s sleep.

From ResMed Corp 15 Sep 2009

Therapy News and Research

Heart failure patients with moderate ejection fractions may benefit from CRT

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

New peptide-based cancer vaccine tested in genital cancer patients

BCLI collaborates with HBI to complete pre-clinical safety experiments

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

HFSA meeting highlights increased risk of heart failure among childhood cancer survivors

Implantable defibrillator therapy not beneficial for women with heart failure

Mantra medicine tool helps patients in healing process

Extension study data on Fampridine-SR drug

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

IMPROVE HF clinical trial results presented at annual HFSA meeting

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

Forest Laboratories places Armour Thyroid medication on back order

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Wake Pharma to present clinical evidence in the treatment of wounds using Wound-Be-Gone at SAWC

New generation CPAP mask to aid sleep apnoea patients from ResMed

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News